Section 5 of 6
Economic information and modeling report
32 evidence topics · 31 sources
Modeling overview
Summary
- Descartes-08 price and revenue: the report holds no announced price for Descartes-08, and the company states that it has no products approved for sale and has not generated any product sales. An analyst page (2024) states that U.S. revenue for Descartes-08 is expected to reach an annual total of $201 mn by 2039 based on GlobalData's Expiry Model. A November 2026 company presentation describes a potential “$1B+ market opportunity for Descartes-08 in the US” and cites “Company internal projections, inclusive of opportunity to retreat patients”.
- Comparator acquisition costs: wholesale acquisition costs of $6,314.19 per vial of Vyvgart ($15.79/mg; 2 or 3 vials per dose, weight based) as of September 30, 2025, and of $16,410.23 per vial ($16.28/mg) and $17,066.64 per syringe ($17.07/mg) of Vyvgart Hytrulo, 1 per dose, as of October 1, 2026; a Rystiggo list price of $3,155.37 per mL (AnalySource, December 2025), dosed in cycles of 1 weekly subcutaneous infusion for 6 weeks; a Zilbrysq list price printed as “$1,1164.21 per 23.0 mg syringe” (AnalySource, January 2026); an Imaavy list price of $12,480 per vial (2025); $6,523 per single-dose vial of Soliris, $5,870.70 per single-dose vial of the biosimilar Bkemv, and $4,566.00 per single dose of Epysqli (2025); and an Uplizna wholesale acquisition cost of $140,248.50 per dose (3 vials), given every six months after two loading doses (2025). Among 5,033 patients in the Optum database (mean body weight 86.6 kg), the annual cost of health-care-provider-administered gMG treatment was estimated at $223,272 to $648,960 depending on drug and body weight, up to $648,960 for patients weighing more than 80 kg. In Medicare drug claims for immune-mediated neurologic disorders, inebilizumab and eculizumab had the highest mean payment per claim in 2022 ($38 993.14).
- ICER 2021 evaluation of eculizumab and efgartigimod: over a 2-year time horizon from a health system perspective, the incremental cost-effectiveness ratio for eculizumab, at an estimated annual cost of $653,100, was $5,210,000 per QALY/evLYG, and efgartigimod was analyzed at a placeholder price of $418,400. The ratio was never less than $3.8 million per QALY/evLYG for eculizumab and $1.7 million for efgartigimod, and in probabilistic sensitivity analyses neither drug reached cost-effectiveness at $150,000 per QALY/evLYG. Health benefit price benchmarks were $13,200 to $19,400 for eculizumab (97%-98% discount from the Federal Supply Schedule price) and $18,300 to $28,400 for efgartigimod, and 8.8% of the eligible population could be treated with efgartigimod at the placeholder price without passing the budget impact threshold.
- Other cost-effectiveness analyses: a lifetime Markov model estimated $3,338,000/QALY gained for eculizumab and $1,987,000/QALY gained for efgartigimod compared with conventional therapy, $3,310,000 and $1,959,000 after indirect costs were applied in a modified societal perspective, with discounts of 93.01% and 88.34% needed for cost-effectiveness. A study that included 31 articles found considerable variability in the costs and cost-effectiveness of MG treatments across regions, therapies, and health care settings. A network meta-analysis of efgartigimod IV, inebilizumab, nipocalimab, ravulizumab, rozanolixizumab, and zilucoplan using 2026 U.S. drug and administration costs found the lowest cost per improved outcome for efgartigimod IV across all QMG and MG-ADL thresholds. From the Canadian publicly funded healthcare system perspective, efgartigimod dominated chronic immunoglobulins (3.45 incremental QALYs and cost savings of $257,020 over a lifetime). From a UK NHS and Personal Social Services perspective, thymectomy plus prednisolone dominated prednisolone alone (0.52 QALYs gained and £13 014 saved per patient). The cost per MG-ADL improvement with IVIg was estimated at 7000-17,000 Japanese yen, lower than that for molecular targeted drugs.
- CAR-T cell therapy costs: a single CAR T-cell infusion was described as approaching USD 500,000, and in a simple model the cumulative costs of systemic lupus erythematosus crossed that reference cost in approximately seven to eight years for very severe disease, 11 years for high disease activity, and 20 years for moderate disease activity. Among 8 patients with systemic lupus erythematosus followed for more than 2 years after CAR T cell therapy, annual direct healthcare costs in the German healthcare service fell from €29,672/year (US $34,353/year) to €3094/year ($3582/year). Among 271 commercially insured patients treated for B-cell lymphoma, median total costs were $608 100, the median cost of CAR-T products was $402 500, and 8.5% had total costs exceeding $1 million. Among 508 patients in a health plan claims database, mean total 30-day costs after infusion were $643,902 in the outpatient cohort and $691,771 in the inpatient cohort. The estimated total cost of care associated with CAR T-cell administration was $454 611 in academic inpatient hospitals and $421 624 in nonacademic specialty oncology networks. Costs of cilta-cel therapy excluding acquisition totaled US$160,933 over 12 months, including $18,268 in pre-infusion costs (apheresis, bridging therapy, and conditioning therapy), against a 2022 wholesale acquisition cost of $465,000. ICER's 2021 multiple myeloma assessment estimated $319,000 per QALY for ide-cel at its wholesale acquisition cost of $419,500 and a health benefit price benchmark of $192,000 to $265,000 per dose.
- CAR-T payment: across 391 Medicare CAR-T claims, 79% were administered in the inpatient setting, and the average Medicare cost was US$498,723 in the inpatient setting and $414,393 in the outpatient setting. An inpatient case is paid through the claim's DRG, with the product included in a single payment for the stay, and a solely outpatient case is paid under the Outpatient Prospective Payment System at Average Sales Price plus 6%. In the FY 2027 final rule, CMS estimated average costs of $64,963 for clinical trial cases and $410,125 for nonclinical trial cases assigned to MS-DRG 018, and a commenter stated that the MS-DRG 018 base payment rate remains insufficient to cover the costs of CAR T-cell and other cellular immunotherapies.
- Eligible population inputs: ICER's 2021 budget impact model used 46,870 U.S. patients with gMG, assumed 100% diagnosis and 20% annual initiation (9,374 additional patients per year), and set initial market shares of 2.27% for eculizumab and 97.73% for conventional therapies. A November 2026 company presentation gives a share of about 85% with AChR antibodies, citing Lazaridis et al., 2020. Treatment-refractory gMG prevalence estimates range from 5% to 15%; among 782 participants in a survey study, 49 (6%) had refractory gMG at enrollment and 201 (26%) were ever-refractory. Among 8759 adults with gMG in Komodo Research Data, use of C5 inhibitors rose from 0.3% to 3.4% and of FcRn blockers from 0.3% to 3.8% between the first (n = 7986) and fifth (n = 3340) treatment episodes.
ICER evaluation of eculizumab and efgartigimod: model framing and base-case results
“The analyses were framed to evaluate results over a 2-year time horizon, taking a health system perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, despite the large impact of changing these inputs on the results, the incremental cost-effectiveness ratio was never less than $3.8 million per QALY/evLYG for eculizumab and $1.7 million per QALY/evLYG for efgartigimod. In probabilistic sensitivity analyses, neither drug was ever found to reach cost-effectiveness at the $150,000 per QALY/evLYG threshold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ICER health benefit price benchmarks and budget impact for eculizumab and efgartigimod
Lifetime U.S. cost-effectiveness of eculizumab and efgartigimod in AChR antibody-positive gMG
“A Markov model with 4 health states was developed, evaluating costs and utility with a 4-week cycle length and lifetime time horizon from a health care system perspective and a modified societal perspective including productivity losses from patients and caregiver burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the corresponding populations, lifetime costs and QALYs, respectively, for eculizumab were $5,515,000 and 11.85, and for conventional therapy, $308,000 and 10.29, resulting in an ICER of $3,338,000/QALY gained. For efgartigimod, lifetime costs and QALYs, respectively, were $6,773,000 and 13.22, and for conventional therapy, $322,000 and 9.98, yielding an ICER of $1,987,000/QALY gained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After applying indirect costs in a modified societal perspective, the ICERs were reduced to $3,310,000/QALY gained for eculizumab and $1,959,000/QALY gained for efgartigimod.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To be considered cost-effective, eculizumab would need to be discounted by 93.01% and efgartigimod by 88.34% of the price that was used in the model’s base case.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs and cost-effectiveness of myasthenia gravis treatments across 31 articles
“The study included 31 articles showing a considerable variability in the costs and cost-effectiveness of MG treatments across regions, therapies, and health care settings. Traditional therapies such as plasma exchange (PLEX) and intravenous immunoglobulin (IVIg) differ notably in cost, with PLEX generally being less expensive. Newer clinically effective treatments such as efgartigimod and eculizumab raise concerns about their economic sustainability, whereas rituximab might be a more affordable alternative in certain contexts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost per improved outcome of approved biologics: network meta-analysis with 2026 U.S. costs
“A de novo NMA was performed using data from Phase III placebo-controlled trials of efgartigimod IV, inebilizumab, nipocalimab, ravulizumab, rozanolixizumab, and zilucoplan, including recently approved therapies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cost per improved outcome (CPIO) was calculated using NNTs and 2026 US drug/administration costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Efgartigimod IV had the lowest CPIO across all QMG and MG-ADL thresholds, significantly lower than almost all other treatments (p < 0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Canadian cost-utility analysis of efgartigimod compared with chronic immunoglobulin
“The analysis was conducted from the perspective of the Canadian publicly funded healthcare system over a lifetime horizon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over a lifetime horizon, efgartigimod and chronic immunoglobulins were predicted to have total discounted QALYs of 16.80 and 13.35 and total discounted costs of $1,913,294 and $2,170,315, respectively. Efgartigimod dominated chronic immunoglobulins with incremental QALYs of 3.45 and cost savings of $257,020.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of thymectomy in nonthymomatous myasthenia gravis: United Kingdom
“The model adopted a UK NHS and Personal Social Services perspective over a lifetime horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the base-case analysis, thymectomy plus prednisolone dominated prednisolone alone, yielding higher health gains (14.63 QALYs vs 14.11 QALYs) and lower lifetime costs (£181 716 vs £194 730). This generated an incremental gain of 0.52 QALYs and a cost saving of £13 014 per patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings support current clinical guidelines recommending thymectomy for eligible patients and establish it as the most relevant comparator in evaluations of future health technologies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost per responder of intravenous immunoglobulin compared with molecular targeted drugs: Japan
“The cost-effectiveness of IVIg and molecular targeted drugs was evaluated using cost per responder and cost per Myasthenia Gravis Activities of Daily Living (MG-ADL) improvement analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The cost per MG-ADL improvement was estimated at 7000-17,000 Japanese yen, which was substantially lower than that for molecular targeted drugs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Direct healthcare costs before and after CD19 CAR-T cell therapy in systemic lupus erythematosus: Germany
“Annual direct healthcare costs were analyzed based on inpatient admissions, emergency department visits, outpatient visits, and prescription drug costs in the German healthcare service.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A preliminary analysis was conducted on 8 patients with SLE (7 female, 1 male; age range 19-38 years) who received CAR T cell therapy and who were followed for > 2 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, CAR T cell therapy led to a substantial decrease in annual direct healthcare costs from €29,672/year (US $34,353/year) to €3094/year ($3582/year) after treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Break-even analysis of a CAR-T cell therapy reference price against cumulative costs of systemic lupus erythematosus: United States
“A single infusion of chimeric antigen receptor (CAR) T-cell therapy (CTCT) is currently expensive, approaching USD 500,000, but the lifetime costs of SLE, including medications, hospitalizations, travel, mental health effects, and lost income, may surpass this figure within years to over a decade, depending on disease severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs for patients with very severe SLE cross the reference CTCT cost in approximately seven to eight years. Estimated breakeven timelines vary by severity level as follows: patients with high disease activity reach breakeven in approximately 11 years, and those with moderate disease activity in approximately 20 years. For mild or inactive SLE, CTCT is not cost-effective at current prices within a clinically meaningful timeframe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Looking forward, emerging strategies, such as off-the-shelf (allogeneic) CTCT, RNA delivery, or hospital-based manufacturing, could reduce CAR T manufacturing costs to USD 80,000 or below [22-24].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We used a simple model to compare the financial burden of living with SLE to the cost of a single dose of CTCT. Our model did not account for all factors, such as inflation, regional cost differences, or changes in insurance coverage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Total cost of care around commercial CAR-T cell therapy for B-cell lymphoma: U.S. commercial claims, 2018 to 2021
“Using the Blue Cross Blue Shield Axis database, we evaluated 271 commercially insured patients who received CAR-T therapy for B-cell lymphoma (median age = 58 years; men = 68%; diffuse large B-cell lymphoma = 87%; inpatient CAR-T therapy = 85%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median total costs were $608 100 (interquartile range, IQR = $534 100-$732 800); 8.5% of patients had total costs exceeding $1 million. The median cost of CAR-T therapy products was $402 500, and the median out-of-pocket copayment was $510. Monthly costs were highest during the month of CAR-T therapy administration (median = $521 500), with median costs below $25 000 in all other 28-day intervals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our study also showed higher costs associated with inpatient CAR-T therapy compared with outpatient therapy delivery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The savings from outpatient delivery accounted for just a small proportion of total costs, however, because of the substantial cost of CAR-T products.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Thirty-day costs after CAR-T cell infusion by setting of care: U.S. commercial claims for diffuse large B-cell lymphoma, 2017 to 2024
“A retrospective cohort study was conducted leveraging IQVIA PharMetrics Plus Health Plans Claims database between January 2017 and March 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 508 patients receiving CAR T infusion and meeting all selection criteria. 442 patients had CAR T administered in the inpatient setting, and 66 had it in the outpatient setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within 30 days following CAR T infusion, 48.5% of the outpatient cohort and 60.9% of patients receiving axi-cel in the outpatient setting had an inpatient stay, with lower rates of intensive care unit admissions (overall: 18.2% vs 43.9%; axi-cel: 39.1% vs 43.5%) and shorter median inpatient stays (overall: 9.0 vs 15.0 days; axi-cel: 11.0 vs 15.0 days) than the inpatient cohort. The mean total 30-day costs appeared lower in the outpatient cohort, overall ($643,902 vs $691,771) and for axi-cel ($695,904 vs $741,449).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare costs and reimbursement of CAR-T cell therapy by setting of care: fee-for-service claims, 2021 to 2022
“Among the total 391 CAR T claims assessed, most of the CAR T therapies were administered in the inpatient setting (79%) compared to outpatient (21%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CAR T therapy in the inpatient setting received an average Medicare cost of US$498,723” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“while the average Medicare cost for outpatient CAR T claims was $414,393” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the higher post-period cost, when looking at the CAR T procedure and pre- and post-periods as a single episode, beneficiaries receiving outpatient CAR T had less cost for the total episode of care ($587,908 vs. $529,188).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When an OP case is admitted into the same hospital within 72 h, the CAR T infusion will be designated by CMS as IP and paid based on the claim's DRG (diagnosis-related grouping). DRG payment rates are set by CMS' Inpatient Prospective Payment System. In IP claims, the CAR T product is not reimbursed individually but rather it is part of a single payment for the entire IP stay. When a case is solely OP (without any IP admission within 72 h), the CAR T product is paid under CMS' Outpatient Prospective Payment System and is set to Average Sales Price (ASP) plus 6%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modeled cost of CAR-T cell therapy administration by site of care: academic inpatient hospital compared with nonacademic specialty oncology network
“The estimated total cost of care associated with the administration of CAR T-cell therapy was $454 611 (95% CI, $452 466-$458 267) in the academic hospital inpatient setting compared with $421 624 (95% CI, $417 204-$422 325) in the nonacademic specialty oncology network setting, for a difference of $32 987. After excluding the CAR T-cell acquisition cost, hospitalization and office visit costs were $53 360 (65.3% of the total cost) in academic inpatient hospitals and $23 526 (48.4% of the total cost) in nonacademic specialty oncology networks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs of CAR-T cell therapy beyond product acquisition, including apheresis: U.S. commercial perspective, multiple myeloma
“The estimated per-patient average costs of cilta-cel CAR-T therapy administered exclusively in an inpatient setting, excluding cilta-cel therapy acquisition costs, totaled US$160,933 over a 12 month period. Costs assuming different proportions of inpatient/outpatient administration (85%/15% and 70%/30%) were US$158,095 and US$155,257, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cost of apheresis was sourced from the CMS 2021 Physician Fee Schedule, a publicly available database [10].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pre-infusion costs including apheresis, bridging therapy, and conditioning therapy totaled $18,268.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our estimated per-patient average costs of cilta-cel CAR-T therapy totaled $160,933, excluding the acquisition cost of cilta-cel, which had a 2022 wholesale acquisition cost of $465,000 [23].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ICER assessment of anti-BCMA CAR-T cell therapies in multiple myeloma: list price, health benefit price benchmarks, and budget impact
Medicare inpatient payment for CAR-T cell therapy: MS-DRG 018 relative weight methodology, FY 2027 final rule
Analyst revenue forecast for Descartes-08, December 2024
Company slide: AChR antibody-positive share and basis of the U.S. market estimate
| Item on the slide | Quoted text |
|---|---|
| Share of the estimated U.S. patient population with AChR antibodies | “~85%” |
| Reference cited for that share | “Lazaridis et al., 2020” |
| Basis stated for the U.S. potential addressable market | “Company internal projections, inclusive of opportunity to retreat patients” |
Vyvgart wholesale acquisition cost per vial, September 2025
| Product and presentation | Wholesale acquisition cost | Price per mg | Vials per dose |
|---|---|---|---|
| VYVGART (efgartigimod alfa-fcab) 400 mg in 20 mL single-dose vial | “$6,314.19” | “$15.79/mg” | “2 or 3 vials per dose (weight based)” |
Vyvgart Hytrulo wholesale acquisition cost per vial and prefilled syringe, October 2026
| Product and presentation | Wholesale acquisition cost | Price per mg | Units per dose |
|---|---|---|---|
| VYVGART Hytrulo single-dose vial, 1,008 mg efgartigimod alfa and 11,200 units hyaluronidase | “$16,410.23” | “$16.28/mg” | “1 vial per dose” |
| VYVGART Hytrulo single-dose prefilled syringe, 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase | “$17,066.64” | “$17.07/mg” | “1 prefill syringe per dose” |
Rystiggo list price per mL, December 2025
Zilbrysq list price per 23.0 mg syringe, January 2026
Soliris and eculizumab biosimilar prices per vial, April 2025
Uplizna wholesale acquisition cost per dose, April 2025
Annual cost of weight-based biologics by body weight: U.S. patients with myasthenia gravis
“Patients from the Optum database (N = 5,033) had mean body weight = 86.6 kg (standard deviation [SD] = 23.1 kg) and median weight = 83.7 kg (interquartile range [IQR] 70.3-99.9 kg).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In each cohort, most patients weighed ≥80 kg (58.0% Optum, 66.2% PSP).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The annual cost of health-care-provider-administered treatment for patients with gMG was estimated at $223,272-$648,960 depending on drug and body weight; annual cost was highest for patients who weighed >80 kg (up to $648,960 versus up to $467,044 for patients who weighed <80 kg).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare Part D payment per claim for immune-mediated neurologic therapies including eculizumab and inebilizumab, 2013 to 2022
“Between 2013 and 2022, 63 unique drugs used as DMTs for multiple sclerosis, neuromyelitis optica spectrum disorder, and other immune-mediated neurologic disorders (eg, autoimmune encephalitis, myasthenia gravis) accounted for 6 526 278 claims and contributed $35 billion in Medicare drug expenditures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 2013, azathioprine had the lowest mean (SD) payment per claim ($36.36 [$29.08]), with immunoglobulins having the highest ($8606.86 [$1121.33]); by 2022, methotrexate was the least costly ($37.35 [$36.71]), with inebilizumab and eculizumab being the most costly ($38 993.14 [$8016.72]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ICER budget impact model: diagnosis assumption, annual uptake, and initial market shares
Proportion with refractory generalized disease: MGFA Patient Registry, United States
“These people are classified as having treatment-refractory gMG, with prevalence estimates ranging from 5% to 15%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 782 participants met the inclusion criteria and were enrolled in the study. Based on the results of the enrollment survey, 49 participants (6%) had refractory gMG. Based on the results from all surveys, 581 participants (74%) were classified as nonrefractory and 201 (26%) as ever-refractory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Use of complement C5 inhibitors, FcRn blockers, and other treatments across successive treatment episodes: U.S. Komodo claims, 2017 to 2025
“Adults with gMG were identified from Komodo Research Data (January 1, 2017-February 28, 2025).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 8759 patients were included (mean age: 61.5 years; 48.7% female; mean follow-up: 36.5 months). From the first (n = 7986) to fifth (n = 3340) treatment episode, AChEi use declined (80.3→57.6%), systemic corticosteroid use was consistent (49.0→63.0%), and use increased for non-steroidal immunosuppressants (12.7→40.2%), immunoglobulin (6.1→14.5%), rituximab (0.3→2.1%), C5i (0.3→3.4%), and FcRn blockers (0.3→3.8%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.